

FOR PUBLIC RELEASE

NZX Limited  
Wellington

Tuesday, 18 April 2023

## **Rua Bioscience Appoints Tony Barclay to its Board, and farewells Brett Gamble**

Rua Bioscience (NZX:RUA) today announces the appointment of Tony Barclay as an Independent Non-Executive Director.

Mr Barclay, who takes up his position on 1 May 2023, is an experienced healthcare industry leader who brings significant financial expertise to Rua.

Mr Barclay was Chief Financial Officer and Company Secretary of Fisher & Paykel Healthcare (FPH) from 2001, when the healthcare business was separated from Fisher & Paykel Appliances, until his retirement in 2018. During his tenure, FPH grew to be one of the largest and most successful companies on the NZX.

Mr Barclay currently serves on the Board of Pacific Edge. He is also the Independent Chair of Australian-based Baymatob, a pioneer in women's health and AI-guided monitoring for pregnancy and labour; and an Independent Director of Veriphi, an Auckland-based technology company developing intravenous drug identity and concentration verification devices.

Rua Bioscience Chair, Trevor Burt says "We are delighted to welcome Tony to the Board. As well as commanding corporate finance expertise, he brings a profound understanding of the challenges faced by export-focused healthcare companies.

"We expect Tony's insight and experience will be invaluable as Rua secures its global supply chain and commercialises its intellectual property," he says.

Mr Barclay succeeds Brett Gamble who joined Rua in 2019 and will retire from the Rua Board effective 30 June 2023. Brett is currently the Chair of the Audit and Risk Committee.

Mr Burt, on behalf of the Board, expresses his sincere appreciation of Mr Gamble's significant contribution to the company during his five-year tenure. Mr Burt said that 'Brett has been a significant contributor to the of the governance team who guided the business through to a NZX listing. We wish Brett all the best for his future and extend our gratitude.'

ENDS

This announcement is authorised by:  
Paul Naske  
Chief Executive Officer, Rua Bioscience